These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37252140)

  • 21. Application of plasma levels of olanzapine and N-desmethyl-olanzapine to monitor metabolic parameters in patients with schizophrenia.
    Lu ML; Chen CH; Kuo PT; Lin CH; Wu TH
    Schizophr Res; 2018 Mar; 193():139-145. PubMed ID: 28720417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate.
    Sun L; Yagoda S; Yao B; Graham C; von Moltke L
    Clin Drug Investig; 2020 Jan; 40(1):55-64. PubMed ID: 31584140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study.
    Correll CU; Stein E; Graham C; DiPetrillo L; Akerman S; Stanford AD; Jiang Y; Yagoda S; McDonnell D; Hopkinson C
    Schizophr Bull; 2023 Mar; 49(2):454-463. PubMed ID: 36305696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets.
    Crocq MA; Guillon MS; Bailey PE; Provost D
    Eur Psychiatry; 2007 Oct; 22(7):453-4. PubMed ID: 17761403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of naltrexone on body fat mass in olanzapine-treated schizophrenic or schizoaffective patients: a randomized double-blind placebo-controlled pilot study.
    Taveira TH; Wu WC; Tschibelu E; Borsook D; Simonson DC; Yamamoto R; Langleben DD; Swift R; Elman I
    J Psychopharmacol; 2014 Apr; 28(4):395-400. PubMed ID: 24218048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder.
    Bobo WV; Bonaccorso S; Jayathilake K; Meltzer HY
    Psychiatry Res; 2011 Sep; 189(2):200-7. PubMed ID: 21802150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Olanzapine activates hepatic mammalian target of rapamycin: new mechanistic insight into metabolic dysregulation with atypical antipsychotic drugs.
    Schmidt RH; Jokinen JD; Massey VL; Falkner KC; Shi X; Yin X; Zhang X; Beier JI; Arteel GE
    J Pharmacol Exp Ther; 2013 Oct; 347(1):126-35. PubMed ID: 23926289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used?
    Faden J; Serdenes R; Citrome L
    Expert Rev Neurother; 2022 May; 22(5):365-376. PubMed ID: 35354374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.
    Hatta K; Otachi T; Fujita K; Morikawa F; Ito S; Tomiyama H; Abe T; Sudo Y; Takebayashi H; Yamashita T; Katayama S; Nakase R; Shirai Y; Usui C; Nakamura H; Ito H; Hirata T; Sawa Y;
    Schizophr Res; 2014 Sep; 158(1-3):213-22. PubMed ID: 25086659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum IL-1ra, a novel biomarker predicting olanzapine-induced hypercholesterolemia and hyperleptinemia in schizophrenia.
    Lin Y; Peng Y; He S; Xu J; Shi Y; Su Y; Zhu C; Zhang X; Zhou R; Cui D
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jun; 84(Pt A):71-78. PubMed ID: 29410009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A potential probiotic bacterium for antipsychotic-induced metabolic syndrome: mechanisms underpinning how Akkermansia muciniphila subtype improves olanzapine-induced glucose homeostasis in mice.
    Huang D; Gao J; Li C; Nong C; Huang W; Zheng X; Li S; Peng Y
    Psychopharmacology (Berl); 2021 Sep; 238(9):2543-2553. PubMed ID: 34046717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625.
    Liebig M; Gossel M; Pratt J; Black M; Haschke G; Elvert R; Juretschke HP; Neumann-Haefelin C; Kramer W; Herling AW
    Obesity (Silver Spring); 2010 Oct; 18(10):1952-8. PubMed ID: 20168311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia.
    Bushe C; Sniadecki J; Bradley AJ; Poole Hoffmann V
    J Psychopharmacol; 2010 Jul; 24(7):1001-9. PubMed ID: 19240085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors of hyperprolactinemia induced by risperidone and olanzapine and their correlations with plasma glucose and lipids.
    He S; Yu WJ; Wang X; Zhang L; Zhao N; Li G; Shen YF; Li H
    Gen Psychiatr; 2020; 33(4):e100206. PubMed ID: 32695960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects.
    Sun L; McDonnell D; Yu M; Kumar V; von Moltke L
    Clin Drug Investig; 2019 May; 39(5):477-484. PubMed ID: 30888624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased food intake and energy expenditure following administration of olanzapine to healthy men.
    Fountaine RJ; Taylor AE; Mancuso JP; Greenway FL; Byerley LO; Smith SR; Most MM; Fryburg DA
    Obesity (Silver Spring); 2010 Aug; 18(8):1646-51. PubMed ID: 20134408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder: A Phase 2, Randomized Clinical Trial.
    Brunette MF; Correll CU; O'Malley SS; McDonnell D; DiPetrillo L; Jiang Y; Simmons A; Silverman BL; Citrome L; Green AI
    J Clin Psychiatry; 2020 Mar; 81(2):. PubMed ID: 32160422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The protective effect of thymoquinone over olanzapine-induced side effects in liver, and metabolic side effects.
    Bilgic S; Tastemir Korkmaz D; Azirak S; Guvenc AN; Kocaman N; Ozer MK
    Bratisl Lek Listy; 2017; 118(10):618-625. PubMed ID: 29198130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Voluntary physical activity protects against olanzapine-induced hyperglycemia.
    Shamshoum H; McKie GL; Medak KD; Ashworth KE; Kemp BE; Wright DC
    J Appl Physiol (1985); 2021 Feb; 130(2):466-478. PubMed ID: 33382959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.
    Sacristán JA; Gómez JC; Montejo AL; Vieta E; Gregor KJ
    Clin Ther; 2000 May; 22(5):583-99. PubMed ID: 10868556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.